Thera leadership team brings decades of experience in the management of start-ups, mid-size and large companies as well as in the discovery, development, and commercialization of $ Billion products.

Scientific Advisors

Key opinion leaders in the field of neurodegenerative disease serve on our Scientific Advisory Board and advise on the scientific strategy and execution of the program.


Thera has established a number of partnerships to advance the discovery and research program.

Antonella Favit-VanPelt, MD, PhD

Guy Maestre, PharmD, MBA
Founder, ad interim Chief Executive Officer

William C. Vincek, PhD
Sr. Vice President, CMC&QA and Preclinical Development

Zdzislaw Wieckowski, JD
Corporate Counsel

Robert H. Brown, MD, PhD

Jeremy M. Shefner, MD, PhD

Richard J. Barohn, MD

Merit E. Cudkovitz, MD

Richard S. Bedlack, MD, PhD

RXi Pharmaceuticals, Marlborough, MA

University of British Columbia, Vancouver, Canada
Neil Cashman, MD
Prof, Brain Research Ctr and Scientific Director, Prionet Canada

Vlaams Instituut voor Biotechnologie, Belgium
Rudy Beyaert, PhD
Associate Department Director and Group Leader VIB Inflammation Research Center



A practicing neurologist, she co-founded Synaerion Therapeutics and Thera Neuropharma inspired by her undying commitment to patients affected by fatal neurologic disorders. She is a pioneer in the field of diagnostic imaging and applied theranostics for the treatment of neurodegenerative disorders and rare diseases. She holds several patents for novel diagnostics and therapeutic agents in the field of Alzheimer’s Disease.
Dr. Favit-VanPelt is also the Founder of StratMedica, an innovative firm specialized in executive leadership for drug development programs and strategic assessment of portfolio opportunities.
Over the years, Dr. Favit-VanPelt has served in leadership positions as US Head of Medical Affairs for Piramal Imaging, Managing Director/Global Head of Regulatory Affairs for the Healthcare Consulting Group, and Chief Development Officer for Personalized Pharmaceuticals. She has covered a number of leadership roles at EMD Serono, Talecris, Amicus Therapeutics, Shire, BMS, and Amersham Health overseeing clinical development and medical programs for pharmacogenetic treatments, biologic agents, prodrug therapeutics, transdermal technologies, and neuroimaging agents.
Dr. Favit-VanPelt received her medical degree in Italy and holds a doctorate in Pharmacology. She trained in the United States publishing extensively in the neuroscience research field.


Mr. Maestre serves as ad interim Chief Executive Officer and Chief Operating Officer of the Company. He is a co-Founder, Board member and Corporate Secretary of the company. He brings over 30 years of pharmaceutical and drug development industry experience from large pharmaceutical and start-up companies.
He is also President & CEO of Popsi Cube, Inc., a CRO specialized in clinical trial implementation. Over the past years, Mr. Maestre has held a number of executive positions serving as President & CEO of two biotech companies, Novactyl and PhenoTech, where he led fundraising, licensing, and development activities. During his tenure in the pharmaceutical industry, Mr. Maestre has held roles of President and CEO of Sodilac-France (a Wyeth affiliate), and Vice-President of International New Product Marketing, and Vice-President of Strategic Planning at Wyeth.
Mr. Maestre obtained his MBA from ESSEC, France. He graduated from the Institut de Pharmacie Industrielle de Montpellier and received his pharmacist degree from the Université de Pharmacie in Montpellier, France.


Dr. Vincek joined Thera as SVP of CMC&QA and Head of Preclinical Development bringing to the company a vast experience in the biotech manufacturing field.
Dr. Vincek is also President of Pharma CMC, Inc., a consulting company providing CMC, regulatory and QA consulting to the Pharmaceutical industry. Prior to founding Pharma CMC, Dr. Vincek served as Sr. Vice-President, Pharmaceutical & Chemical Development, Guilford Pharmaceuticals. At Guilford, Dr. Vincek was instrumental in leading the biopolymer platform innovative technology bridging two translational programs to registration stage (Aquavant) and approval (Aggrastat®).
In his career, Dr. Vincek has held various CMC leadership roles at Glaxo Wellcome, Inc., SmithKline Beecham Pharmaceuticals and related entities.


Mr. Wieckowski is Thera's general counsel.  He brings to the company a long- standing domestic and international experience in the pharma / biotech / medical device corporate law.
His tenure expands to financing deals, mergers and acquisitions, distribution agreements, cross-border tax structuring, competition law, and FCPA investigations.  He has spent a good portion of his career overseas representing Western financial and strategic investors, completing corporate transactions in over forty countries across EMA.
Prior to joining Thera, Mr. Wieckowski he has been a partner at well-known global British and American law firms, including White & Case where he was the head of the corporate group in and the CFO/COO of the firm's Warsaw office. He has served on the boards of directors of several stock exchange listed investment funds.
He holds a Juris Doctor from Harvard Law School, and trained at Boston University and Boston College.




Dr. Brown is presently Chair of the Department of Neurology at the University of Massachusetts Medical School. He has become internationally recognized for his work on the inherited basis of neurodegenerative and neuromuscular diseases. Dr. Brown is a pioneer with a remarkable record of significant discoveries in amyotrophic lateral sclerosis (ALS) and neuromuscular disorders.


Dr. Shefner is Chair of the Department of Neurology, Professor of Neurology, and Associate Director of Barrow Neurological Institute. Dr. Shefner is the founder and co-chair of the Northeast ALS Clinical Trials Consortium (NEALS) and has pioneered work using Motor Unit Number Estimation in detecting and following treatment outcomes.


Dr. Barohn serves as Professor and Chairman of the Department of Neurology at the University of Kansas Medical Center in Kansas City. He served on the national medical advisory boards for the Myasthenia Gravis Foundation and the Guillain-Barre Syndrome Foundation International and The Myositis Association.


Dr. Cudkowicz serves as Chief of Neurology at Massachusetts General Hospital at Harvard Medical School. Dr. Cudkowicz co-directs the MGH Amyotrophic Lateral Sclerosis (ALS) clinic and the Neurology Clinical Trials Unit (NCTU) at MGH Partners Healthcare System and Northeast ALS Consortium.


Dr. Bedlack is presently Associate Professor of Medicine/Neurology at Duke, Director of the Duke ALS Clinic, and Chief of Neurology at the Durham Veterans Affairs Medical Center. He has won awards for teaching and patient care, including best Neurology teacher at Duke, Health Care Hero, Strength Hope and Caring Award, America’s Best Doctor, the American Academy of Neurology Patient Advocate of the Year and the Rasmussen ALS Patient Advocate of the Year.